Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Has announcements × Octreotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

pembrolizumab 42 Carboplatin 37 Cisplatin 32 Paclitaxel 26 Pemetrexed 22 Nivolumab 22 Gemcitabine 21 Dexamethasone 19 Rituximab 17 Ipilimumab 16 Cyclophosphamide 15 Lenalidomide 12 Fluorouracil 12 atezolizumab 11 Docetaxel 11 Capecitabine 11 trastuzumab deruxtecan 10 durvalumab 10 daratumumab 10 Prednisone 10 Cytarabine 10 Bevacizumab 10 olaparib 9 Bortezomib 9 Trastuzumab 8 Leucovorin 8 Doxorubicin 8 130-nm albumin-bound paclitaxel 8 zanubrutinib 7 venetoclax 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01578239 2022-04-04

NETTER-1

Advanced Accelerator Applications

Phase 3 Completed

231 enrolled 16 charts 2 FDA

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡